Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCTA Immunotherapy in Recurrent Glioblastoma Multiforme
NCT04277221Phase 3Unknown
- Sponsor
- Safe Save Medical Cell Sciences & Technology Co., Ltd.
- Start
- Sep 2019
- Primary completion
- Dec 2022
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of autologous tumor-loaded dendritic cells in glioblastoma (GBM), sponsored by Safe Save Medical Cell Sciences & Technology Co., Ltd.. Status: unknown.
02
Drugs
autologous tumor-loaded dendritic cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04277221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04277221.